Pregabalin Capsule
Product Images NDC 71205-323

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 71205-323). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Proficient Rx Lp, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

71205-323-90 (Pregabalin Caps 100mg 90s Count)

Label for Pregabalin 100 mg capsules by Proficient Rx LP. The package contains 90 capsules, each with 100 mg pregabalin. Capsules are described as white to off-white powder in size "3" hard gelatin capsules with orange opaque caps and orange opaque bodies, imprinted with "SG" on the cap and "353" on the body in black ink. The label includes NDC 71205-323-90 and states prescription use only (C-V schedule). Manufacturer is ScieGen Pharmaceuticals, Inc.*

FDA Label Image

Figure 1 (Pregabalin Fig01)

A line graph depicting the percent of patients improved versus percent improvement in pain from baseline. The graph compares Pregabalin at 200 mg, 100 mg, and 25 mg taken three times a day, along with a placebo. The x-axis shows percent improvement in pain, and the y-axis shows the percent of patients improved.*

FDA Label Image

Figure 2 (Pregabalin Fig02)

A line graph comparing the percent of patients improved against the percent improvement in pain from baseline. It features two plotted lines representing 'Pregabalin 100 mg three times a day' and 'Placebo', showing patient improvement percentages across different pain improvement thresholds.*

FDA Label Image

Figure 3 (Pregabalin Fig03)

A line graph comparing percent improvement in pain from baseline against percent of patients improved for Pregabalin at doses of 75 mg, 150 mg, and 300 mg taken twice daily, as well as placebo. The graph shows a trend of increasing patient improvement percentages with higher doses of Pregabalin compared to placebo.*

FDA Label Image

Figure 4 (Pregabalin Fig04)

A line graph showing percent improvement in pain from baseline on the x-axis and percent of patients improved on the y-axis. It compares three groups: Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, and placebo, illustrating patient response rates across varying levels of pain improvement.*

FDA Label Image

Figure 5 (Pregabalin Fig05)

A line chart comparing the percent improvement in pain from baseline with pregabalin 100 mg three times a day, pregabalin 50 mg three times a day, and placebo. The vertical axis shows the percent of patients improved, and the horizontal axis shows the percent improvement in pain from baseline. The graph illustrates differences in pain improvement distributions among the three groups.*

FDA Label Image

Figure 6 (Pregabalin Fig06)

A bar chart comparing responder rates (%) in two clinical studies (E1 and E3) for different doses of pregabalin versus placebo. Study E1 includes placebo, 50 mg/day, 150 mg/day, 300 mg/day, and 600 mg/day doses, showing increasing responder rates up to 51%. Study E3 includes placebo, 300 mg/day, and 600 mg/day doses with responder rates up to 49%. Statistically significant differences from placebo are noted.*

FDA Label Image

Figure 7 (Pregabalin Fig07)

A line graph showing seizure reduction as median percent change from baseline relative to dose in mg/day. Four study groups are represented with different markers, showing increased seizure reduction with higher doses, with significant p-values indicated for various points. The graph includes a dose of zero representing placebo.*

FDA Label Image

Figure 9 (Pregabalin Fig08)

A line graph depicting the percent of patients improved versus percent improvement in pain from baseline. It compares Pregabalin at daily doses of 800 mg, 450 mg, and 300 mg against placebo, showing trends of patient improvement across different pain reduction percentages.*

FDA Label Image

Figure 10 (Pregabalin Fig09)

A Kaplan-Meier survival curve graph comparing Pregabalin and placebo over 180 days. The graph shows the estimated percentage of subjects without LTR on the y-axis and days on the x-axis, illustrating a higher survival rate for subjects treated with Pregabalin compared to placebo over time.*

FDA Label Image

Figure 11 (Pregabalin Fig10)

Line graph depicting the percent of subjects improved over percent improvement from baseline to Week 12 BOCF, comparing Pregabalin and placebo groups. The y-axis shows percent of subjects improved from 0% to 100%, and the x-axis shows percent improved from baseline to Week 12 BOCF from 0 to 100. Pregabalin consistently shows a higher percentage of improved subjects than placebo across the spectrum.*

FDA Label Image

Figure 12 (Pregabalin Fig11)

A line graph comparing the percent of subjects improved from baseline to week 16 BOCF for Pregabalin versus placebo. The x-axis represents the percent improved from baseline to week 16 BOCF, ranging from 0 to over 100%. The y-axis shows the percent of subjects improved, ranging from 0 to 100%. The graph has one solid line for Pregabalin and one dashed line for placebo, illustrating higher improvement percentages in the Pregabalin group compared to placebo across the range.*

FDA Label Image

Cockcroft And Gault Equation (Pregabalin Formula)

Mathematical formula text panel showing the calculation of creatinine clearance (CLcr) using age, weight, serum creatinine, and a factor for female patients. The formula is depicted as (140 - age in years) multiplied by weight in kg, divided by 72 times serum creatinine in mg/dL, with a multiplication factor of 0.85 for females.*

FDA Label Image

Chemical Structure (Pregabalin Str)

Chemical structure diagram of the active ingredient pregabalin, showing its molecular framework including an amine group, carboxylic acid group, and hydrocarbon side chains.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.